Publications 2013

De Lastours V, LeGoff J, Brière J, Agbalika F, Boulet T, Lévy Y, Simon F, Aboulker J-P and Molina J-M. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial. HIV Médecine (2013) Lien PubMed 

Launay O, Surenaud M, Desaint C, Ben Hamouda N, Pialoux G, Bonnet B, Poizot-Martin I, Gonzales G, Cuzin L, Bourgault-Villada I, Lévy Y, Choppin J, Durier C. Long-term CD4+ and CD8+ T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).Vaccine 2013 Jul 11. j.vaccine.2013.06.102. Lien PubMed

Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, De Castro N, Caron F, Braun J, Molina JM and the ANRS 138 Easier study group. Decreases in Inflammatory and Coagulation Biomarkers Levels in HIV-Infected Patients Switching from Enfuvirtide to Raltegravir: ANRS 138 Substudy. J Infect Dis2013, 208 : 892-897. Lien PubMed

Richert L, Hue S, Hocini H, Raimbault M, Lacabaratz C, Surenaud M, Wiedemann A, Tisserand P, Durier C, Salmon D, Lelièvre JD, Chêne G, Thiébaut R, Lévy Y; ANRS Vaccine Network/Vaccine Research Institute. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers.AIDS. 2013 Jun 1;27(9):1421-31. Lien PubMed

Richert L, Thiebaut R; Biostatistics Bioinformatics Division of the ANRS Vaccine Research Institute.Is the current use of 'positivity' thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints? AIDS. 2013 May 15;27(8):1362-5. Collaborators: Richert L, Durier C, Surenaud M, Targat B, Wiedemann A, Hue S, Hocini H, Lacabaratz C, Legrand R, Thiébaut R. 

Bunupuradah T, Duong T, Compagnucci A, McMaster P, Bernardi S, Kanjanavanit S, Rampon O, Faye A, Saïdi Y, Riault Y, De Rossi A, Klein N, Ananworanich J, Gibb D; PENTA 11 Extension Study Group. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.AIDS. 2013 Feb 20;27(4):579-89. Lien PubMed
Durier C, Desaint C, Lucht F, Girard PM, Lévy Y, May T, Michelet C, Rami A, Roman F, Delfraissy JF, Aboulker JP, Launay O; for the ANRS 151 study group and the REIVAC network. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03A adjuvant in HIV-1-infected adults AIDS. 2013 Jan 2;27(1):87-93.Lien PubMed

Harrison L, Ananworanich J, Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Forcat S, Riault Y, Lallemant M, Castro H, Gibb DM, Giaquinto C; Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team.Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children: AIDSBehav. 2013 Jan;17(1):193-202. Lien PubMed